Hepatocellular Carcinoma
Conditions
Brief summary
The purpose of this study is to determine whether TAC-101 as a second line therapy for participants who received Sorafenib as first line therapy is effective in slowing tumor activity in patients with advanced hepatocellular carcinoma. The study is also looking at the safety of TAC-101 following treatment with Sorafenib.
Detailed description
Advanced metastatic hepatocellular carcinoma (HCC) is not treatable by surgical approaches or locoregional therapies such as hepatic artery hemoembolization or radiofrequency ablation (RFA) which are effective in controlling localized tumors. Currently marketed systemic chemotherapy agents, with the exception of sorafenib, provide marginal benefit. Despite the demonstrated survival benefit from sorafenib, it is still imperative to improve to the effectiveness of systemic therapy in this patient population. Studies of TAC-101, a synthetic retinoid, indicate that although TAC-101 may not induce tumor regression, it appears to have a stabilizing effect, prolonging survival over what was expected historically. This Phase 2, randomized, double-blind, placebo-controlled international, multicenter study is designed to evaluate the efficacy and safety of TAC 101 as second line treatment in patients with advanced HCC following treatment with sorafenib as first-line therapy. Sorafenib has recently been approved as first line treatment for HCC in the EU and the US and is expected to become the standard of care for the first-line treatment of advanced HCC. Aside from best supportive care, there is no second line therapy available for HCC. It is hypothesized that TAC 101 treatment can extend Overall Survival (OS) after discontinuation of sorafenib.
Interventions
DRUGTAC-101
Participants were randomized to TAC 101 received TAC 101 20 mg (administered as 2 10 mg formulated tablets) PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) for 14 days followed by a 7 day recovery period. This cycle was repeated every 21 days.
DRUGPlacebo
Participants randomized to placebo received 2 placebo tablets (identical in appearance to the TAC 101 tablets) administered PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) in a regimen identical to that for TAC 101.
Sponsors
Quintiles, Inc.
Taiho Oncology, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Provide written informed consent prior to performance of any study procedures. * Is at least 18 years of age. * Have a diagnosis of advanced unresectable histologically confirmed HCC (excluding fibrolamellar carcinoma). * Have discontinued from first line treatment with sorafenib monotherapy for any reason (ie, tumor disease progression, intolerance) at least 14 days prior to planned randomization but have not received any second line treatment for HCC. * Have recovered from any significant sorafenib-related treatment toxicities prior to randomization (Grade 1). * Have at least 1 target lesion that is viable (has vascularization) and can be accurately measured according to RECIST. * Patients who have received local therapy prior to sorafenib administration (radiation, surgery, hepatic arterial embolization, chemoembolization, RFA, percutaneous ethanol injection \[PEI\] or cryoablation) are eligible. Local therapy must be completed at least 4 weeks prior to the baseline scan. * Have ECOG score of 0, 1, or 2. * Child-Pugh score \<8. * Have adequate organ function defined as: * Platelet count great than 50, less than 109/L; * Hemoglobin 8.0 g/dL; * Total bilirubin 3 mg/dL; * Alanine transaminase (ALT) and aspartate aminotransferase (AST) less than or equal to 5 X ULN; * Serum creatinine 1.5 X ULN; * PT-international normalized ratio (INR) 2.3 or PT 6 seconds above control * Total white blood cell (WBC) count 2.0 109/L * Is able to take medications orally (eg, no feeding tube). * Women of childbearing potential must have a negative pregnancy test (urine or serum) prior to randomization and within 2 days prior to starting the study drug. Females must agree to adequate non-estrogenic birth control if conception is possible during the study; and males must agree to adequate birth control during the study and up to 6 months after the discontinuation of study medication.
Exclusion criteria
* History of DVT, PE, myocardial infarction (MI), CVA, transitory ischemic attack (TIA), or any other significant TE during the last 3 years. * Have clinically significant symptoms of hepatic encephalopathy or known brain metastasis. * Patients who have had clinically significant acute gastrointestinal bleeding as a result of portal vein hypertension within 4 weeks prior to randomization are excluded; however, patients with a history of acute gastrointestinal bleeding that have received appropriate treatment, ie, ligation of varices, are eligible. * Are receiving therapeutic regimens of anticoagulants, with the exception of prophylaxis care of indwelling venous access devices. * Have received a liver transplant. * Are taking prohibited medication. * Have received a previous systemic therapy (including investigational agents) other than sorafenib (see Inclusion Criterion 4) for treatment of HCC. Patients participating in surveys or observational studies are eligible to participate in this study. * Have had treatment with any of the following within the specified timeframe prior to randomization: * Any sorafenib within the 14 days prior to randomization. * Major surgery within the 4 weeks prior to randomization. * Any transfusion, treatment with blood component preparation, received. erythropoietin , albumin preparation, and granulocyte colony-stimulating factor (G CSF) within the 2 weeks prior to randomization. * Has a serious illness or medical condition(s) including, but not limited to the following: * Known gastrointestinal disorder, including malabsorption, chronic nausea, vomiting, or diarrhea present to the extent that it might interfere with oral intake and absorption of the study medication. * Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness. * Previous or concurrent malignancy except for basal cell carcinoma and/or in situ carcinoma of the cervix, or other solid tumor treated curatively and without evidence of recurrence for at least 3 years prior to the study. * Uncontrolled metabolic disorders or other nonmalignant organ or systemic diseases or secondary effects of cancer that induce a high medical risk and/or make assessment of survival uncertain. * Has active or uncontrolled clinically serious infection excluding chronic hepatitis. * Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the patient inappropriate for entry into this study (eg, active urinary tract infection). * Known allergy or hypersensitivity of TAC 101 and any other components used in the TAC 101 tablet.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | From the date of randomization to date of death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months) | OS was defined as the time from the date of randomization to the date of death. Participants who were still alive were censored at the date last known to be alive (last contact date or last follow-up visit). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time To Progression (TTP) | From the date of randomization to date of tumor disease progression or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months) | TTP was defined as time from randomization to the date of tumor progression (radiological only). Participants who were alive with no tumor progression or who died prior to tumor progression had their TTP censored at the date of their last tumor assessment, unless they received new antitumor therapy. |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | From Baseline up to 30 days after the last dose (maximum duration: up to 7.2 months for Placebo and up to 7.9 months for TAC-101) | Any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily have a causal relationship with the use of the study treatment was considered an AE. A serious AE (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs (both serious/non-serious) that occur from the initiation of any study medication administration, and do not necessarily have a causal relationship to the use of the study medication. |
| Change From Baseline in Plasma Levels of the Tumor Marker Alpha-fetoprotein (AFP) | From the date of randomization to date of tumor disease progression or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months) | AFP is a tumor marker for hepatocellular carcinoma and elevations in AFP values could precede clinical deterioration and tumor recurrence in participants. Baseline was defined as the last value obtained within 72 hours prior to study treatment administration on Cycle 1 Day 1. |
| Percent Change From Baseline in Plasma Levels of the Tumor Marker Alpha Fetoprotein-L3 (AFP-L3) | From the date of randomization to date of tumor disease progression or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months) | AFP-L3 is a tumor marker for hepatocellular carcinoma and elevations in AFP-L3 values could precede clinical deterioration and tumor recurrence in participants. Baseline was defined as the last value obtained within 72 hours prior to study treatment administration on Cycle 1 Day 1. |
| Maximum Exposure-response Analysis: Maximum Plasma Concentration (Cmax) of TAC-101 | Cycle 1-day 1: 4, 8, and 24 hours after the first dose of study drug | Cmax: maximum plasma concentration; Pharmacokinetic (PK) blood samples were collected at 4 hours (± 1 hour), 8 hours (± 1 hour), and 24 hours (± 1 hour) post-dose on Day 1 of treatment Cycle 1. The 24-hour sample was collected prior to dosing on Day 2. |
| Overall Exposure-response Analysis: Area Under Curve (AUC0-inf) of TAC-101 | Cycle 1-day 1: 4, 8, and 24 hours after the first dose of study drug | AUC(0-inf): Area under the curve from time zero extrapolated to infinity. PK blood samples were collected at 4 hours (± 1 hour), 8 hours (± 1 hour), and 24 hours (± 1 hour) post-dose on Day 1 of treatment Cycle 1. The 24-hour sample was collected prior to dosing on Day 2. |
| Changes From Baseline in Plasma Insulin-like Growth Factor-2 (IGF-2) | From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months) | RAR related factors are markers for disease progression in hepatocellular carcinoma participants. In hepatocellular carcinoma participants, IGF-2 is a characteristic biomarkers and its levels are higher in responder cells. The detection of IGF-2 levels showed the efficacy of TAC-101 in IGF-2 influenced malignancy. |
| Radiologic Progression-free Survival (PFS) | From the date of randomization to date of tumor disease progression or death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months) | PFS was defined as the time from date of randomization to the date of tumor disease progression (ie, radiological only) or death due to any cause. Participants who were alive at the time of analysis and had no signs of tumor progression had their time of PFS censored at the date of the last tumor assessment, unless they received new antitumor therapy. |
| Changes From Baseline in Plasma Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) | From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months) | IGFBP-3 acts as a mediator of antiproliferative signals in hepatocellular carcinoma cells. The inhibition of hepatocellular carcinoma cell proliferation is associated with upregulation of IGFBP-3. Retinoic acid response element (RARE) exists on the promoter region of the IGFBP-3. |
| Changes From Baseline in Plasma Insulin-like Growth Factor Binding Protein-6 (IGFBP-6) | From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months) | IGFBP-6 has an IGF-2 binding specificity and inhibits growth of a number of IGF-2-dependent cancers. RARE exists on the promoter region of the IGFBP-6. |
| Changes From Baseline in Plasma Lactoferrin | From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months) | RARE exists on the promoter region of the lactoferrin gene. |
| Changes From Baseline in Plasma Vascular Endothelial Growth Factor-A (VEGF-A) | From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months) | End of Treatment was defined as as soon as possible following the last dose of study medication. |
| Number of Participants With Antitumor Activity After Treatment Discontinuation | From the date of treatment discontinuation to date of tumor disease progression or death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months) | Antitumor activity after treatment discontinuation in participant was determined by images, computed tomography (CT), and magnetic resonance imaging (MRI). Tumor imaging was done at Baseline any time within 4 weeks prior to the first dose of study treatment on Cycle 1, Day 1 and every 6 weeks (±1 week) during treatment, regardless of a dose delay. If participant discontinued study treatment for a reason other than disease progression (PD), data collected every 6 weeks until PD and following PD, data collected optionally every 6 weeks until death or up to 1 year after the last participant was randomized. |
| Relationship Between Tumor Gene Expression of Messenger Ribonucleic Acid (mRNA) Ratio of Co-activators, Co-repressors and Efficacy Parameters | At Baseline (prior to treatment after consenting informed consent form [ICF]) up to last dose of study treatment, assessed every 6 weeks (maximum duration: up to 21.3 months) | The assessment of correlative factors was to be conducted on tissue removed prior to the study, if available. Tumor tissue assessments included investigation of the relationship between tumor gene mRNA expression of co-activators and co-repressors and efficacy parameters. |
| Changes From Baseline in Plasma Transforming Growth Factor-beta (TGFβ2) | From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months) | TGF-β is responsible for tissue regeneration, cell differentiation, embryonic development, and regulation of the immune system. TGF-β2 levels are higher in non-responder cells hence helps in detection of such cells. |
Countries
Italy
Participant flow
Recruitment details
The study was conducted at 17 study centers worldwide between 01-August-2008 to 10-May-2010.
Pre-assignment details
The study was stopped after only 52 of the required 220 participants (26 of 110 participants in each treatment group) were randomized. Sponsor terminated the study due to safety concerns and thus, stopped enrollment and study treatment on 06-May-2009, but continued follow-up of all the treated participants for survival till 10 May 2010 and thus, the same was considered as study completion date.
Participants by arm
| Arm | Count |
|---|---|
| TAC-101 Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion. | 26 |
| Placebo Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion. | 26 |
| Total | 52 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event (AE) | 10 | 3 |
| Overall Study | Clinical Disease Progression | 1 | 3 |
| Overall Study | Investigator Discretion | 3 | 1 |
| Overall Study | Radiological Disease Progression | 6 | 2 |
| Overall Study | Sponsor Terminated Study | 6 | 17 |
Baseline characteristics
| Characteristic | Placebo | Total | TAC-101 |
|---|---|---|---|
| Age, Continuous | 68.2 years STANDARD_DEVIATION 6.38 | 69.7 years STANDARD_DEVIATION 6.75 | 71.1 years STANDARD_DEVIATION 6.93 |
| Race/Ethnicity, Customized Asian | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Black, of African Heritage | 2 Participants | 2 Participants | 0 Participants |
| Race/Ethnicity, Customized Other: Unspecified | 0 Participants | 2 Participants | 2 Participants |
| Race/Ethnicity, Customized White | 24 Participants | 47 Participants | 23 Participants |
| Sex: Female, Male Female | 4 Participants | 7 Participants | 3 Participants |
| Sex: Female, Male Male | 22 Participants | 45 Participants | 23 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 2 / 26 | 6 / 26 |
| other Total, other adverse events | 25 / 26 | 24 / 26 |
| serious Total, serious adverse events | 12 / 26 | 11 / 26 |
Outcome results
Primary
Overall Survival (OS)
OS was defined as the time from the date of randomization to the date of death. Participants who were still alive were censored at the date last known to be alive (last contact date or last follow-up visit).
Time frame: From the date of randomization to date of death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)
Population: Analysis was performed on safety population that included all randomized participants who received at least one dose of double-blind study medication and was summarized by the treatment received.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TAC-101 | Overall Survival (OS) | 8.23 months | Standard Deviation 5.406 |
| Placebo | Overall Survival (OS) | 8.35 months | Standard Deviation 5.351 |
Secondary
Change From Baseline in Plasma Levels of the Tumor Marker Alpha-fetoprotein (AFP)
AFP is a tumor marker for hepatocellular carcinoma and elevations in AFP values could precede clinical deterioration and tumor recurrence in participants. Baseline was defined as the last value obtained within 72 hours prior to study treatment administration on Cycle 1 Day 1.
Time frame: From the date of randomization to date of tumor disease progression or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)
Population: Analysis was performed on safety population that included all randomized participants who received at least 1 dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TAC-101 | Change From Baseline in Plasma Levels of the Tumor Marker Alpha-fetoprotein (AFP) | 2779.3 nanogram per milliliter (ng/mL) | Standard Deviation 16314.87 |
| Placebo | Change From Baseline in Plasma Levels of the Tumor Marker Alpha-fetoprotein (AFP) | 571.7 nanogram per milliliter (ng/mL) | Standard Deviation 14301.08 |
Secondary
Changes From Baseline in Plasma Insulin-like Growth Factor-2 (IGF-2)
RAR related factors are markers for disease progression in hepatocellular carcinoma participants. In hepatocellular carcinoma participants, IGF-2 is a characteristic biomarkers and its levels are higher in responder cells. The detection of IGF-2 levels showed the efficacy of TAC-101 in IGF-2 influenced malignancy.
Time frame: From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)
Population: Analysis was performed on safety population that included all randomized participants who received at least 1 dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TAC-101 | Changes From Baseline in Plasma Insulin-like Growth Factor-2 (IGF-2) | 330.8 ng/mL | Standard Deviation 87.82 |
| Placebo | Changes From Baseline in Plasma Insulin-like Growth Factor-2 (IGF-2) | 115.6 ng/mL | Standard Deviation 181.59 |
Secondary
Changes From Baseline in Plasma Insulin-like Growth Factor Binding Protein-3 (IGFBP-3)
IGFBP-3 acts as a mediator of antiproliferative signals in hepatocellular carcinoma cells. The inhibition of hepatocellular carcinoma cell proliferation is associated with upregulation of IGFBP-3. Retinoic acid response element (RARE) exists on the promoter region of the IGFBP-3.
Time frame: From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)
Population: Analysis was performed on safety population that included all randomized participants who received at least 1 dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TAC-101 | Changes From Baseline in Plasma Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) | 370.6 ng/mL | Standard Deviation 242.97 |
| Placebo | Changes From Baseline in Plasma Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) | -112.4 ng/mL | Standard Deviation 179.64 |
Secondary
Changes From Baseline in Plasma Insulin-like Growth Factor Binding Protein-6 (IGFBP-6)
IGFBP-6 has an IGF-2 binding specificity and inhibits growth of a number of IGF-2-dependent cancers. RARE exists on the promoter region of the IGFBP-6.
Time frame: From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)
Population: Analysis was performed on safety population that included all randomized participants who received at least 1 dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TAC-101 | Changes From Baseline in Plasma Insulin-like Growth Factor Binding Protein-6 (IGFBP-6) | -40.7 ng/mL | Standard Deviation 82.08 |
| Placebo | Changes From Baseline in Plasma Insulin-like Growth Factor Binding Protein-6 (IGFBP-6) | -86.9 ng/mL | Standard Deviation 72.82 |
Secondary
Changes From Baseline in Plasma Lactoferrin
RARE exists on the promoter region of the lactoferrin gene.
Time frame: From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)
Population: Analysis was performed on safety population that included all randomized participants who received at least 1 dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TAC-101 | Changes From Baseline in Plasma Lactoferrin | -133.3 ng/mL | Standard Deviation 177.2 |
| Placebo | Changes From Baseline in Plasma Lactoferrin | -25.5 ng/mL | Standard Deviation 25.83 |
Secondary
Changes From Baseline in Plasma Transforming Growth Factor-beta (TGFβ2)
TGF-β is responsible for tissue regeneration, cell differentiation, embryonic development, and regulation of the immune system. TGF-β2 levels are higher in non-responder cells hence helps in detection of such cells.
Time frame: From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)
Population: Analysis was performed on safety population that included all randomized participants who received at least 1 dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TAC-101 | Changes From Baseline in Plasma Transforming Growth Factor-beta (TGFβ2) | -3.51 picograms per milliliter (pg/mL) | Standard Deviation 4.957 |
| Placebo | Changes From Baseline in Plasma Transforming Growth Factor-beta (TGFβ2) | 0.92 picograms per milliliter (pg/mL) | Standard Deviation 2.427 |
Secondary
Changes From Baseline in Plasma Vascular Endothelial Growth Factor-A (VEGF-A)
End of Treatment was defined as as soon as possible following the last dose of study medication.
Time frame: From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)
Population: Analysis was performed on safety population that included all randomized participants who received at least 1 dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TAC-101 | Changes From Baseline in Plasma Vascular Endothelial Growth Factor-A (VEGF-A) | -29.50 pg/mL | Standard Deviation 51.859 |
| Placebo | Changes From Baseline in Plasma Vascular Endothelial Growth Factor-A (VEGF-A) | 11.40 pg/mL | Standard Deviation 83.141 |
Secondary
Maximum Exposure-response Analysis: Maximum Plasma Concentration (Cmax) of TAC-101
Cmax: maximum plasma concentration; Pharmacokinetic (PK) blood samples were collected at 4 hours (± 1 hour), 8 hours (± 1 hour), and 24 hours (± 1 hour) post-dose on Day 1 of treatment Cycle 1. The 24-hour sample was collected prior to dosing on Day 2.
Time frame: Cycle 1-day 1: 4, 8, and 24 hours after the first dose of study drug
Population: PK population included all participants in safety population participating in this sub-study and treated with active study treatment. Due to limited number of participants with evaluable PK data, no data was collected and analyzed for the conclusion of maximum exposure. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.
Secondary
Number of Participants With Antitumor Activity After Treatment Discontinuation
Antitumor activity after treatment discontinuation in participant was determined by images, computed tomography (CT), and magnetic resonance imaging (MRI). Tumor imaging was done at Baseline any time within 4 weeks prior to the first dose of study treatment on Cycle 1, Day 1 and every 6 weeks (±1 week) during treatment, regardless of a dose delay. If participant discontinued study treatment for a reason other than disease progression (PD), data collected every 6 weeks until PD and following PD, data collected optionally every 6 weeks until death or up to 1 year after the last participant was randomized.
Time frame: From the date of treatment discontinuation to date of tumor disease progression or death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)
Population: The data were not collected and analyzed for this outcome measure due to low enrollment of participants.
Secondary
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
Any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily have a causal relationship with the use of the study treatment was considered an AE. A serious AE (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs (both serious/non-serious) that occur from the initiation of any study medication administration, and do not necessarily have a causal relationship to the use of the study medication.
Time frame: From Baseline up to 30 days after the last dose (maximum duration: up to 7.2 months for Placebo and up to 7.9 months for TAC-101)
Population: Analysis was performed on safety population that included all randomized participants who received at least one dose of double-blind study medication and was summarized by the treatment received.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TAC-101 | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | TEAE | 26 Participants |
| TAC-101 | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | TESAE | 12 Participants |
| Placebo | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | TEAE | 25 Participants |
| Placebo | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | TESAE | 11 Participants |
Secondary
Overall Exposure-response Analysis: Area Under Curve (AUC0-inf) of TAC-101
AUC(0-inf): Area under the curve from time zero extrapolated to infinity. PK blood samples were collected at 4 hours (± 1 hour), 8 hours (± 1 hour), and 24 hours (± 1 hour) post-dose on Day 1 of treatment Cycle 1. The 24-hour sample was collected prior to dosing on Day 2.
Time frame: Cycle 1-day 1: 4, 8, and 24 hours after the first dose of study drug
Population: PK population included all participants in safety population participating in this sub-study and treated with active study treatment. Due to limited number of participants with evaluable PK data, no data was collected and analyzed for conclusion of maximum exposure. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.
Secondary
Percent Change From Baseline in Plasma Levels of the Tumor Marker Alpha Fetoprotein-L3 (AFP-L3)
AFP-L3 is a tumor marker for hepatocellular carcinoma and elevations in AFP-L3 values could precede clinical deterioration and tumor recurrence in participants. Baseline was defined as the last value obtained within 72 hours prior to study treatment administration on Cycle 1 Day 1.
Time frame: From the date of randomization to date of tumor disease progression or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)
Population: Analysis was performed on safety population that included all randomized participants who received at least 1 dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TAC-101 | Percent Change From Baseline in Plasma Levels of the Tumor Marker Alpha Fetoprotein-L3 (AFP-L3) | 2.27 percent change | Standard Deviation 12.107 |
| Placebo | Percent Change From Baseline in Plasma Levels of the Tumor Marker Alpha Fetoprotein-L3 (AFP-L3) | 3.20 percent change | Standard Deviation 8.129 |
Secondary
Radiologic Progression-free Survival (PFS)
PFS was defined as the time from date of randomization to the date of tumor disease progression (ie, radiological only) or death due to any cause. Participants who were alive at the time of analysis and had no signs of tumor progression had their time of PFS censored at the date of the last tumor assessment, unless they received new antitumor therapy.
Time frame: From the date of randomization to date of tumor disease progression or death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)
Population: Analysis was performed on safety population that included all randomized participants who received at least one dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TAC-101 | Radiologic Progression-free Survival (PFS) | 4.95 months | Standard Deviation 4.904 |
| Placebo | Radiologic Progression-free Survival (PFS) | 4.82 months | Standard Deviation 3.647 |
Secondary
Relationship Between Tumor Gene Expression of Messenger Ribonucleic Acid (mRNA) Ratio of Co-activators, Co-repressors and Efficacy Parameters
The assessment of correlative factors was to be conducted on tissue removed prior to the study, if available. Tumor tissue assessments included investigation of the relationship between tumor gene mRNA expression of co-activators and co-repressors and efficacy parameters.
Time frame: At Baseline (prior to treatment after consenting informed consent form [ICF]) up to last dose of study treatment, assessed every 6 weeks (maximum duration: up to 21.3 months)
Population: The data were not collected and analyzed for this outcome measure due to low enrollment of participants.
Secondary
Time To Progression (TTP)
TTP was defined as time from randomization to the date of tumor progression (radiological only). Participants who were alive with no tumor progression or who died prior to tumor progression had their TTP censored at the date of their last tumor assessment, unless they received new antitumor therapy.
Time frame: From the date of randomization to date of tumor disease progression or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)
Population: Analysis was performed on safety population that included all randomized participants who received at least one dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TAC-101 | Time To Progression (TTP) | 4.14 months | Standard Deviation 4.43 |
| Placebo | Time To Progression (TTP) | 4.09 months | Standard Deviation 3.146 |